Bruce L. Levine, PhD University of Pennsylvania

Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is Founding Director of the Clinical Cell and Vaccine Production Facility at the University of Pennsylvania. He received a B.A. (Biology) from Penn and Ph.D. (Immunology and Infectious Diseases) from Johns Hopkins. First-in-human clinical trials include the first use of a lentiviral vector and first infusions of gene edited cells. Dr. Levine has overseen the production of 3,000 cellular products administered to >1,200 patients since 1996. He is co-inventor of the first FDA approved gene therapy (Kymriah), chimeric antigen receptor T cells for leukemia and lymphoma. Dr. Levine is co-inventor on 26 issued US patents and co-author of >180 manuscripts and book chapters with a Google Scholar citation h-index of 83. He is a Co-Founder of Tmunity Therapeutics, a spinout of the University of Pennsylvania. Dr. Levine has received the William Osler Patient Oriented Research Award, the Wallace Coulter Award for Healthcare Innovation, will serve as President Elect of the International Society for Cell and Gene Therapy (2020-2022). He has written for Scientific American and Wired and has been interviewed by the NY Times, Wall Street Journal, Washington Post, NPR, BBC, Time, National Geographic, Bloomberg, and Forbes.